glp 1 drugs how long have they been around Chart: in 8 Americans Now Use GLP-1 for Weight Loss The Evolution of GLP-1 Users

Description

If you wish to know more, check our complete GLP-1 healthtech market playbook

Newer drugs like Mounjaro (Tirzepatide) combine GLP-1 and GIP (Glucose-Dependent Insulinotropic Peptide) effects

Call and talk to a specialist today

[DOI] [PubMed] [Google Scholar] 35.Bahne E, Hansen M, Brnden A, Sonne DP, Vilsbll T, Knop FK

6 Department of Diabetes and Endocrinology, Birmingham Heartlands Hospital, Birmingham, UK Correspondence: Konstantinos A Toulis Department of Endocrinology, Diabetes and Metabolism, 424 General Military Hospital, Thessaloniki, Greece Tel +30 231 038 1902 Email [email protected] *These authors contributed equally to this work Abstract: Glucagon-like peptide 1 receptor agonists (GLP1-RA) are prominent agents in the therapeutics of type 2 diabetes mellitus due to their exemplary efficacy in both preprandial and postprandial glycemia, their safety, low risk of hypoglycemia, their multilevel pathophysiological superiority, weight loss and importantly the observed benefits in cardiovascular disease reduction